CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. - Wikidata - awgldk - TriplyDB

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

http://www.wikidata.org/entity/Q33367168

about

Analysis of the genome to personalize therapy for melanoma Updates of mTOR inhibitors Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy Targeting the mTOR signaling network for cancer therapy Melanoma: from mutations to medicine PI3K/PTEN signaling in angiogenesis and tumorigenesis Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.State of melanoma: an historic overview of a field in transition.The PIK3CA gene as a mutated target for cancer therapy.In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.Exploiting novel molecular targets in gastrointestinal cancers.Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma Targeted therapy for melanoma: a primer.Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma.Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.Novel targeted therapies for the treatment of metastatic melanoma.New horizons in melanoma treatment: targeting molecular pathways.A phase II study of gefitinib in patients with metastatic melanoma.Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Targeted agents for the treatment of metastatic melanoma.The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.Targeting drivers of melanoma with synthetic small molecules and phytochemicals.AKT1 Activation Promotes Development of Melanoma Metastases.Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.Therapeutic interventions to disrupt the protein synthetic machinery in melanoma Metabolic complications with the use of mTOR inhibitors for cancer therapy Investigating mammalian target of rapamycin inhibitors for their anticancer properties.Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.New approaches in metastatic melanoma: biological and molecular targeted therapies.

P2860

Q24601008-6B2ECAE5-D740-4C5C-9CEA-A3827323787D Q24607170-DE01320A-A69C-4969-A96F-44FF758BB223 Q24628724-0E2A5947-E1CD-455F-9384-0F6311C7A1A7 Q24658334-4C513133-AAE8-4F74-88D7-1F541AA916B8 Q27024061-2F378118-8E93-4120-BCA5-A4AEBDC1D791 Q28383083-4B883B6D-5AFB-4774-A47D-B855C280FE7E Q30412106-AFCFE0CA-1ACE-46BE-B1DA-3081A04F9B22 Q30415894-E07A9AE6-9CF7-438A-AC12-84C66FAC64F1 Q33383550-F40F7052-5A21-4304-B60B-8F6FDBF994CA Q33389796-3662A079-B95E-4884-8F88-0E72B20AC1FD Q33394687-C3859F61-8AC8-480E-85E8-BCB66B35F64E Q33399049-25CD16E4-2980-4C43-99A8-486D1CFEF03C Q33693906-6C7E4F41-7CAE-48F1-B90B-AAC3DAD426D0 Q33699378-F2305B33-2FBE-4C15-8104-2C62F9B11290 Q33755862-4F08C980-07B2-4E4E-B542-40E1D623E82C Q33822119-576B273D-6642-4BB2-B8D5-B1B5378CB9C8 Q34372987-8ACADC98-0D3E-4B8C-A4E7-0140DB9EEA17 Q34382777-8B45798B-CA46-4AE5-8CD3-B3504CEAE2A9 Q34497045-BDD765F4-0646-45BD-9B4D-FE8F2099B5DD Q34540273-ACFB8F7F-1EBA-42BC-A6E0-74AD0A3CDE61 Q34576062-28D8803F-566C-4A5A-B6A0-48578B7264B7 Q34682072-0A6A4A76-5014-438B-95B9-BCFA1E974256 Q34758583-12385848-9D0E-412B-B238-C441BE221A77 Q34986178-4984A79C-714B-4C43-A5FD-9A525B3822C7 Q34986188-050B6720-CDA4-491A-9A56-56C62936DFEE Q35093992-A143DA6D-4F35-4457-BC9B-E7ADE1D979BC Q35581006-27FE6823-DCF1-4C97-8599-5EE7B8C83FD8 Q35679353-77B48DC8-1C28-4BAC-829A-5CD7A6E87DEB Q35822194-6DB0F6A5-BE03-4AC6-8722-936EB706CE8B Q35911227-D915D74B-31DE-4C53-A730-D03FC9881999 Q35992132-BCE28354-9532-4067-BD07-FDBDBA5B2F8F Q36141097-EEB77C05-6197-40D1-8B2E-6FF9D03EB0FD Q36284645-1B52739D-F4A3-4D8A-BF04-E5DC8921560C Q36347314-84DB27E5-1789-4331-A17F-34E0298E1754 Q36352100-BF73D62F-53CE-4D23-8FE0-DA44AC700062 Q36473355-8D8F0F2E-74F4-4DB4-B6BA-CE93F2EE96E5 Q36553517-A26C61F8-7986-4273-9BF5-1C8AA1932D8A Q36600294-7270E27C-8E41-40B0-90E6-6B0451A3CA2B Q36649565-4015B149-D0EC-457E-9F38-7EDFE98D47F5 Q36817127-21B5CA99-1A33-431B-A82F-F6C6F86A9DC5

P2860

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

http://www.wikidata.org/entity/Q33367168

description

2005 nî lūn-bûn

@nan

2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

@ast

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

@en

type

label

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

@ast

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

@en

prefLabel

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

@ast

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

@en

P1433

Q33367168-A3126935-E66F-4DE9-8A01-37CFF2870C2C

P1476

Q33367168-BAF77F07-674D-4C2E-9797-551EA3863629

P2093

Q33367168-018854AB-43FB-4566-BA12-7BBFEEB3CD8A

Q33367168-1C50E3AC-86B4-4EA8-8E8B-C05A83F5A367

Q33367168-4A8FA413-641B-42E7-99E6-1F48511E696A

Q33367168-87E51562-EB6F-4AA4-8116-14F4678D67DB

Q33367168-99BBC262-D2C1-4914-8CE1-0757AF565567

Q33367168-B4C5ADFB-5B68-423E-8359-A72DBE9D472F

Q33367168-F01145B1-6318-4A73-9B2C-92B9718129AA

Q33367168-F9CBB927-144D-4858-9B97-68500C323AD0

P2860

Q33367168-62C29E01-2D4B-4C23-9A00-CA645AC165F8

P304

Q33367168-1CC2FA18-C6B3-47B4-869B-9BA2EAFBDCE6

P31

Q33367168-BE6E28E5-3EC5-4B9A-A9A2-B16366A093BF

P356

Q33367168-F0192CC3-BEDE-4025-A381-D886D9D0A419

P407

Q33367168-C87DAD18-C949-49B7-848C-DA854AC1C82E

P433

Q33367168-B59043AA-7B16-49FA-96EC-7D1787E29A9C

P478

Q33367168-7B98825C-9572-4EEC-A006-7ACE27288B7D

P50

Q33367168-8FAEE4EA-6261-4322-849A-56B4C3ECE5A6

P577

Q33367168-2E1DEA9B-50AC-4FAE-83AC-8400426BF3E3

P5875

Q33367168-ABDCE19C-5251-4EC3-B32E-5BE71E5294B0

P698

Q33367168-7189455F-9BD8-4254-BCC8-06AF0058551E

P921

Q33367168-6C7A0835-7FB0-42DB-B24B-A2F509C28DA6

Q33367168-D24C2639-D65A-4C69-A775-769C302E7405

P356

P1433

P1476

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

@en

P2093

Ian Quirt

http://www.w3.org/2001/XMLSchema#string

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Jeffrey Weber

http://www.w3.org/2001/XMLSchema#string

Kim Margolin

http://www.w3.org/2001/XMLSchema#string

Scott Christensen

http://www.w3.org/2001/XMLSchema#string

Thomas Gajewski

http://www.w3.org/2001/XMLSchema#string

Tim Synold

http://www.w3.org/2001/XMLSchema#string

Tracey Baratta

http://www.w3.org/2001/XMLSchema#string

P2860

Uncommon presentations of Hodgkin's disease. Case 1. Hodgkin's disease of the jejunum.

P304

1045-1048

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.21265

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229670391

http://www.w3.org/2001/XMLSchema#string

P698

16007689

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial